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Abstract: The functional and prognostic signiﬁcance of pulmonary hypertension (PH) is well established, yet
our understanding of circulating peptides and metabolites that might mark or contribute to various forms of
PH remains limited. Metabolites are the end result of all the regulatory complexity present in a cell, tissue,
or organism and therefore serve as the most proximal reporters of the body’s response to a disease process or
drug therapy. This review presents the rationale, methodology, and preliminary ﬁndings from studies that
apply comprehensive metabolite proﬁling to gain knowledge of new circulating markers of PH.
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The development of elevated pulmonary arterial pressure
(PAP), either in unselected populations or in individuals
with a variety of cardiopulmonary diseases, is associated
with poor prognosis.
1-5 Pulmonary hypertension (PH, i.e.,
meanPAP>25mmHg)leadstorightventricular(RV)dys-






3,9 Despite the functional and prog-
nostic signiﬁcance of right ventricular–pulmonary vas-
cular (RV-PV) dysfunction, peptides and metabolites that
might mark or contribute to RV-PV dysfunction remain
incompletely deﬁned. Knowledge of new circulating mark-
ers of RV-PV dysfunction or susceptibility to RV-PV dys-
function may provide more precise estimates of risk while
also deﬁning the pathways perturbed in individual patients,
revealing new targets for intervention and ultimately en-
abling an individualized approach to care.
10,11
To address unmet needs in disease biomarkers, inves-
tigators have turned to comprehensive proﬁling of large
numbers of endogenous metabolites and proteins in bio-
ﬂuids, which has been termed “metabolomics” and “prote-
omics,” respectively (Figure 1). Metabolites are the end re-
sult of all the regulatory complexity present in a cell, tissue,
ororganism,includingtranscriptionalandtranslationalreg-
ulation as well as posttranslational modiﬁcations. There-
fore, metabolites are the most proximal reporters of the
body’s response to a disease process or drug therapy (Fig-
ure 2). As described below, emerging metabolomics tech-
niques will allow us to “overlay” new biomarkers and multi-
marker scores on existing cardiovascular disease diagnostic
tests.
12 It is anticipated that some new markers will be un-
correlatedwithor“orthogonal”toexistingmarkers,thuspro-
viding additional pathobiological insights and informa-
tion for cardiovascular disease management.
13 In addition
to serving as disease biomarkers, circulating metabolites
may themselves participate in previously unanticipated
roles as regulatory signals with hormone-like functions.
14
METHODS FOR METABOLIC PROFILING
Present estimates suggest that the human metabolome con-
sists of approximately 3,000–5,000 endogenous small mole-
cules (i.e., <1 kDa in size), as described in the Human Me-
tabolome Project (http://www.hmdb.ca), and ∼40,000 total
metabolites, including exogenous compounds originating
from nutrients, microbiota, drugs, and other sources.
15,16
The metabolome spans a variety of chemical compound
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lipophilic versus hydrophilic. Therefore, no single analytical
methodis capableof analyzing allmetabolites.
Two core technologies are utilized to perform meta-
bolic proﬁling: nuclear magnetic resonance (NMR) and
tandem mass spectrometry (MS/MS). For recent reviews of




19 NMR requires relatively lit-
tle sample preparation and is nondestructive, allowing for
subsequent structural analyses. However, the method tends
to have low sensitivity and can detect only highly abundant
analytes. MS/MS coupled with liquid chromatography (LC),
on the other hand, has higher sensitivity for small mole-
cules and is also applicable to a wide range of biological
ﬂuids (including serum, plasma, and urine). Recent ad-
vances in MS technology now enable researchers to deter-
mine analyte masses with such high precision and ac-
curacy that metabolites can be identiﬁed unambiguously
even in complex ﬂuids.
19
These technologies can be used to characterize biolog-
ical samples either in a targeted manner or in a pattern dis-
covery manner. In the former, the investigator targets a
predeﬁned set of metabolites for analysis. In the latter, the
investigator is faced with a complex pattern of peaks, many
of which are anonymous: the molecular identities of the
species giving rise to the peaks are generally not known.
While the targeted approach is more limited, the analysis
is more straightforward, as the biochemicals giving rise
to the signals have already been identiﬁed. An example of
metabolite coverage by a targeted platform that is being ac-
tively applied to metabolic proﬁling of cardiovascular dis-
eases
20-23 is shown in Table 1. This platform can acquire
the data for 290 metabolites in ∼60 minutes from less than
200 μL of plasma. As can be seen in Table 1, the platform
Figure 1. Rapid expansion of proteomics and metabolomics in
biomedical research: the number of annual publications in me-
tabolomics from 2001 to 2012. Criteria for inclusion of publi-
cations included the terms “metabolome” and “metabolomics.”
A color version of this ﬁgure is available online.
Figure 2. Integration of “omics” approaches and their relationship to phenotype. AA: amino acids; OA: organic acids; CHO:
carbohydrates. A color version of this ﬁgure is available online.
418 | Role of metabolomics in developing biomarkers Lewisprovides nearly uniform coverage of all pathways in the
KEGG database. Selection of metabolites for incorporation
into our platform is based on (1) their biological diver-
sity (i.e., “sentinels” in as many of the known metabolic
pathways as possible), (2) their biological relevance (i.e.,
arginine-nitric oxide [NO] signaling pathway intermedi-
ates), and (3) their ability to be detected by LC-MS methods.
The pattern discovery, or ﬁngerprint, approach is inher-
ently less biased, but the need for subsequent unambigu-
ous identiﬁcation of the peaks can be difﬁcult.
STATISTICAL APPROACHES AND DATA
REDUCTION FOR “OMICS” APPROACHES
Although high-throughput metabolomics approaches to
biomarker discovery bringmanyadvantages, they also bring
the danger of generating false-positive associations as a re-
sult of multiple testing and overﬁtting of data. Replication
is imperative to minimize overﬁtting of data.
24 Application
of traditional statistical approaches (e.g., Bonferroni cor-
rection) in this setting tends to levy an insurmountable
statistical penalty that can obscure biologically relevant as-
sociations. Newer statistical techniques,
25 such as advanced
resampling methods or control of the false-discovery rate,
26
coupled with functional trend analysis in which changes in
constituents of common pathways are analyzed together,
can aid in detecting subtle but important changes in multi-
ple variables identiﬁed in “omics” approaches.
27-29 Several
data reductionstrategiescanbeusedtoconstructmultivari-
ate metabolite biomarker proﬁles,
30 including discriminant
analysis,
31 partial least squares, principal components anal-
ysis,
32and artiﬁcial neural networks.
33
APPLICATION OF METABOLOMICS FOR
CARDIOVASCULAR BIOMARKER DISCOVERY
A very limited number of metabolites, such as glucose,
lipids, creatinine, urea, and uric acid, have been used for
decades to assess an individual’s (pre-)disease condition. In
1971, Arthur Robinson and Linus Pauling
34 conceived the
core ideathatinformation-richdatareﬂectingthe functional
status of a complex biological system resides in the quanti-
tative and qualitative pattern of metabolites in body ﬂuids.
Currently, in the ﬁeld of inborn errors of metabolism, an
extensive repertoire of metabolites is used as biomarkers
for diagnosis, progression, and response to treatment.
35 As
might be expected, the application of metabolomics to com-
plex cardiovascular diseases with multiple potential clin-
ical confounders (i.e., medication exposure, age, gender,
comorbidities) has been more difﬁcult than that to Mende-
lian disorders.
36 Interindividual variability and adequacy
of signal-to-noise intensity for certain metabolites repre-
sent additional hurdles in metabolomics studies.
To help circumvent these problems, investigators have
applied these emerging technologies to unique clinical sce-
narios where serial sampling can be performed in patients
both before and after a controlled perturbation, thereby al-
lowing each patient to serve as his or her own biological
control.
20,21,29 As proof of principle, our group has applied
targeted MS-based metabolomics to patients undergoing
“planned myocardial ischemia,”
21,22,29 elicited by exercise,
and “planned myocardial infarction,”
20 induced by alcohol
septal ablation in patients with hypertrophic obstructive
cardiomyopathy. In both cases, robust metabolic changes
were evident within minutes of the physiologic perturba-
tion, when traditional markers of myocardial injury such
as troponin remained unchanged.
A global metabolomics analysis of plasma revealed a
pathway in both humans and mice linking microbiota me-
tabolism of dietary choline and phosphatidylcholine to car-
diovascular disease pathogenesis.
37 Metabolic proﬁling has
also demonstrated distinct patterns of myocardial substrate
utilization in individuals undergoing surgical coronary re-
vascularization. Turer et al.
38 found that patients with left
ventricular dysfunction demonstrated global suppression
of metabolic fuel uptake and limited myocardial meta-
bolic reserve and ﬂexibility after global ischemia/reperfu-
sion stress in the setting of cardiac surgery. Shah and col-
leagues
39 used a targeted MS/MS-based platform to proﬁle
69 metabolites so as to evaluate suspected ischemic heart dis-
ease in more than 600 subjects from the Duke CATHGEN
Table 1. Approximate coverage of KEGG metabolism areas
Human metabolites
Metabolism area Number Coverage, %
Amino acid metabolism 370 21
Nucleotide metabolism 109 46
Carbohydrate metabolism 236 20
Energy metabolism 80 44
Metabolism of cofactors and vitamins 148 22
Metabolism of other amino acids 105 30
Biosynthesis of secondary metabolites 114 20
Lipid metabolism 284 15
Biodegradation of xenobiotics 180 6
Biosynthesis of polyketides and
nonribosomal peptides 18 22
Glycan biosynthesis and metabolism 90 4
Note: KEGG: Kyoto encyclopedia of genes and genomes.
16
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demonstrated that peripheral blood metabolite proﬁles, one
enriched for branched-chain amino acid metabolites and
another comprising urea cycle metabolites, add to the dis-
criminative capability for coronary artery disease, compared
with models containing only clinical variables.
METABOLOMICS IN PH
The proﬁling of metabolites, including lipids, sugars,
amino acids, and amines, is particularly relevant to RV-
PV dysfunction. Some circulating metabolites (i.e., cyclic
guanosine monophosphate [cGMP] and other NO path-
way intermediates such as arginine, asymmetric dimethyl-
arginine [ADMA], ornithine, citrulline, tryptophan hydrox-
ylase metabolites, and catecholamines) have already been
implicated in mediating pulmonary vascular tone, as de-
scribed below. Altered metabolic substrate utilization, in
the form of a mitochondrial metabolic switch from glu-
cose oxidation to glycolysis, has been observed in the set-
ting of PV remodeling,
40,41 RV hypertrophy,
42 and RV dys-
function,
43 offering further incentives to apply metabolite
proﬁling to PH in left ventricular dysfunction. Through
metabolomic proﬁling studies in PH, it will be important
to ascertain the extent to which plasma metabolite levels
reﬂect alterations in RV-PV metabolism while also evaluat-
ing small molecules with known vasoactive properties, as
well as metabolites not previously associated with PH, as
potential biomarkers ofRV-PV dysfunction.
There is an emerging paradigm of PH as a systemic,
multiorgandiseasecharacterizedbymitochondrial dysfunc-
tion.
44 Mitochondria integrate inputs regarding fuel supply
(oxygen, glucose, lipids) and have recently been recognized
to secrete mitokines that act on distant organs. This excit-
ing work suggests that when mitochondria from one organ
become dysfunctional, they can signal mitochondria from
other tissues by releasing diffusible factors termed mito-
kines.
45 PH patients demonstrate insulin resistance in skel-
etal muscle analogous to observations in type 2 diabetes.
This is particularly relevant because circulating metabolite
clusters consisting of elevated levels of branched-chain and
aromatic amino acids have been shown to independently
predict future onset of insulin resistance and diabetes more
than a decade before overt disease onset.
23
Recently, Fessel and colleagues
46 reported ﬁndings from
metabolomic analyses of human pulmonary microvascular
endothelial cells expressing two different disease-causing
mutations in the bone morphogenetic protein receptor
type 2 gene (BMPR2). This study conﬁrmed previously de-
scribed increases in glycolysis but also found signiﬁcant
upregulation of the pentose phosphate pathway, increases
in nucleotide salvage and polyamine biosynthesis path-
ways, decreases in fatty acid oxidation pathways, and im-
pairment of tricarboxylic acid (TCA) cycle anaplerosis. The
study went on to conﬁrm increased isocitrate dehydroge-
nase activity in the setting of elevated isocitrate levels in
BMPR2-mutant cells. This proof-of-principle study pro-
vides insight into potential metabolic pathways altered in
RV-PV dysfunction beyond the primary focus to date on
alteredglucose homeostasisin PH.
Plasma-based metabolomics studies in PH are just be-
ginning to emerge. One recent study in a porcine model
of pulmonary embolism examined pre- versus postembo-
lism plasma metabolite levels and found alterations in me-
tabolites relatedto energybalance in hypoxic conditions, in-
cluding glycolysis-derived metabolites, ketone bodies, and
TCA cycle intermediates.
47 The extent to which easily mea-
sured circulating metabolite levels will reﬂect metabolic
changes in experimental models requires further inves-
tigation. For example, physiologic perturbations such as
hypoxia and exercise can result in increases in circulating
TCA cycle intermediates,
21 which may or may not reﬂect
intracellular TCA cycle activity.
METABOLOMICS IN WHO GROUP 2 PH
There may be a particularly important role for applica-
tion of metabolite proﬁling in furthering understanding
of RV-PV dysfunction in the setting of left-heart disease
(i.e., WHO group 2 PH). Heart failure (HF) due to left ven-
tricular systolic dysfunction (LVSD) is commonly associat-
ed with the development of PH.
6 However, the ability of
the RV to respond to increased PAP at rest and during
exercise is highly variable in HF and remains poorly un-
derstood.
48 S t u d i e si nb o t he x p e r i m e n t a lm o d e l sa n dp a -
tients have suggested a maladaptive imbalance between
small-molecule pulmonary vasodilators and vasoconstric-
tors in HF. Altered NO signaling, including decreased NO
synthase (NOS) bioavailability and increased production of
endogenous small-molecule NOS inhibitors (i.e., ADMA),
may contribute to the pathophysiology of PH in HF.
49
Like impaired NO responsiveness, decreased production
of prostacyclin (PGI2) and dysregulation of PGI2 metabo-
lism may also contribute to PH in LVSD.
50 Furthermore,
insulin resistance with decreased peroxisome proliferator-
activated receptor g activation can accelerate adverse re-
modeling of the pulmonary vasculature in HF.
51
Shao et al.
52 recently reported that arginine-NO path-
way intermediates can distinguish patients with differ-
ential burdens of WHO group 2 PH. Melenovsky et al.
53
found that impaired transpulmonary cGMP release rela-
tive to transpulmonary B-type natriuretic peptide uptake
420 | Role of metabolomics in developing biomarkers Lewiswas present in HF patients with high pulmonary vascu-
lar resistance and that phosphodiesterase-5 inhibition re-
stored cGMP responsiveness. That study is an example of
careful physiologic phenotyping with multisite sampling
that can serve as a basis for potentially inferring local me-
tabolism in the pulmonary circulation via measurement of
circulatingsmallmoleculessuchascGMP.Whilethesestud-
ies provide promise that circulating markers of arginine-
NO pathway intermediates associate with hemodynamic
proﬁles, further investigations are needed to determine
whether circulating metabolite levels from metabolic pro-
ﬁling will predict responses to therapies and prognosis in
RV-PV dysfunction.
CONCLUSION
Although metabolomics technologies are still under devel-
opment, they complement other functional genomic ap-
proaches, such as high-throughput genome sequencing
and RNA expression analysis.
54 Together, they hold great
promise to transform our ability to proﬁle samples and
discover multiple new biomarkers for RV-PV dysfunction.
Novel multimarker approaches may also permit identiﬁ-
cation of alterations in speciﬁc pathways to inform the
best preventative and therapeutic interventions for each
individual, by restoring the speciﬁc perturbed pathways to
their normal function.
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